A Phase 1a/1b Dose Escalation and Expansion Study of Single-agent SC-002 in Subjects With Relapsed or Refractory Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
| Registry | NCT02500914 |
|---|---|
| Status | Terminated - Strategic Considerations |
| Phase | Phase 1 |
| Study type | Interventional; na, single group, masking: none, treatment |
| Enrollment | 35 (Actual) |
| Sponsor | Stemcentrx (Industry) |
| Conditions | Small Cell Lung Cancer |
| Interventions | SC-002 (Drug) |
| Dates | start 2015-06-01, primary completion 2018-08-23, completion 2018-08-23, first posted 2015-07-17, last updated 2018-10-05 |
| Locations | 4 sites in United States |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Small Cell Lung Cancer All trials of SC-002
This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). SC-002 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy.
The purpose of this study is to assess the safety and tolerability of SC-002 at different dose levels, to determine the highest dose of SC-002 that can be given to patients with SCLC or LCNEC, to evaluate the side effects of SC-002, and to assess the anti-cancer activity of SC-002.
Part 1A is a dose escalation study in patients with small cell lung cancer or large cell neuroendocrine carcinoma with cytologically confirmed, limited or extensive SCLC or LCNEC that have relapsed or refractory limited or extensive disease following no more than 2 prior chemotherapy regimens.
Part 1B is an expansion study where patients will be enrolled and treated in order to further characterize safety and preliminary efficacy in patients with SCLC or LCNEC and further characterize PK, immunogenicity and target expression and possible relationship to clinical outcome.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| SC-002 | Experimental | Drug: SC-002 | Part 1A (Dose Escalation) - IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose (MTD) or lower dose that provides adequate PK exposure, immunogenicity, and preliminary evidence of antitumor activity with tolerability. Part 1B (Dose Expansion) - IV infusion; once MTD and/or RD has been determined in Part 1A, an expansion cohort of approximately 60 patients with SCLC or LCNEC will be enrolled to further characterize the safety profile and clinical activity of the RD. Patients may continue treatment until disease progression, unacceptable toxicity, or withdrawal of consent. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Histologically or cytologically confirmed SCLC (either limited or extensive disease) or LCNEC, that has relapsed from the most current treatment or was refractory to treatment * Evidence of progressive disease during or following no more than 2 prior chemotherapy regimens * Measurable disease as defined by RECIST * ECOG performance status of 0 or 1 * Adequate hematological and organ function as confirmed by laboratory values * Treatment with anticancer/investigational drugs, therapy ≤ 4 weeks prior to first dose of SC-002 Exclusion Criteria: * Active central nervous system metastases * Uncontrolled cardiac disease * Positive serology for hepatitis B or hepatitis C or known HIV infection * Presence of any condition that may increase the risks associated with study participation and interfere with the interpretation of study results
| Facility | City | Country | Status |
|---|---|---|---|
| Ann Arbor, Michigan | United States | ||
| St Louis, Missouri | United States | ||
| New York, New York | United States | ||
| Nashville, Tennessee | United States |